Clinigence receives $3M strategic equity investment from ApolloMed; issues shares and warrants

Nutex Health Inc.

ApolloMed invests $3M; Clinigence issues 1M shares at $3.00 and warrants for 500k shares at $3.50.
Brandon Sim (ApolloMed COO/CTO) appointed to board; director Elisa Luqman resigns, remains Secretary.
Investment closed Sept 30, 2021; funding received Oct 1, 2021 – strengthens balance sheet for NASDAQ uplisting.
ApolloMed will nominate one director; shares issued as private placement exempt from SEC registration.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brandon Sim

Director

NUTX · Nutex Health Inc.

Filed: October 1, 2021, 7:59 PM ET

the Board of Directors (the “Board”) of Company appointed Brandon Sim, to the Board of Directors.

Departed

Elisa Luqman

Director

NUTX · Nutex Health Inc.

Filed: October 1, 2021, 7:59 PM ET

the Board of Directors (the “Board”) of Clinigence Holdings, Inc. (the “Company”) accepted the resignation of Elisa Luqman from the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brandon Sim was appointed as Director at Nutex Health Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of Company appointed Brandon Sim, to the Board of Directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Elisa Luqman resigned as Director at Nutex Health Inc..

Action: resigned
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of Clinigence Holdings, Inc. (the “Company”) accepted the resignation of Elisa Luqman from the Board.

View on SEC.gov

Nutex Health Inc. filing history →

Source: SEC EDGAR

accession 0001607062-21-000375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.